In This Article:
Multiple insiders secured a larger position in CG Oncology, Inc. (NASDAQ:CGON) shares over the last 12 months. This is reassuring as this suggests that insiders have increased optimism about the company's prospects.
Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for CG Oncology
The Last 12 Months Of Insider Transactions At CG Oncology
Over the last year, we can see that the biggest insider purchase was by Independent Director Hong Fang Song for US$5.0m worth of shares, at about US$19.00 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of US$35.47. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.
CG Oncology insiders may have bought shares in the last year, but they didn't sell any. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying.
Insider Ownership Of CG Oncology
Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. CG Oncology insiders own about US$170m worth of shares (which is 7.0% of the company). I like to see this level of insider ownership, because it increases the chances that management are thinking about the best interests of shareholders.
So What Does This Data Suggest About CG Oncology Insiders?
It doesn't really mean much that no insider has traded CG Oncology shares in the last quarter. However, our analysis of transactions over the last year is heartening. Judging from their transactions, and high insider ownership, CG Oncology insiders feel good about the company's future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. Case in point: We've spotted 2 warning signs for CG Oncology you should be aware of, and 1 of these can't be ignored.
Of course CG Oncology may not be the best stock to buy. So you may wish to see this free collection of high quality companies.